What type of study is this?

December 8, 2025Blood

Real-world survival outcomes with first-line venetoclax therapy in AML

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals lower overall survival in AML patients with resistance mutations, suggesting new stratification approaches.

Overall survival was significantly lower in AML patients with resistance mutations such as TP53 compared to those without.
In a registry of 160 patients receiving venetoclax with azacitidine or decitabine, median age at diagnosis was 72 years.
The analysis highlights the critical role of resistance mutations in developing treatment plans for AML.
Implications point to the need for updated risk stratification based on resistance and sensitivity mutations in clinical settings.

Mitchell et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals lower overall survival in AML patients with resistance mutations, suggesting new stratification approaches.

Overall survival was significantly lower in AML patients with resistance mutations such as TP53 compared to those without.
In a registry of 160 patients receiving venetoclax with azacitidine or decitabine, median age at diagnosis was 72 years.
The analysis highlights the critical role of resistance mutations in developing treatment plans for AML.
Implications point to the need for updated risk stratification based on resistance and sensitivity mutations in clinical settings.

Mitchell et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark